| Document |
Document Title |
|
WO/2023/077070A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/072297A1 |
The present disclosure relates to a nitrogen-containing tetracyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a nitrogen-containing tetracyclic compound r...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/072816A1 |
The invention relates to a multiantennary glycolipid mimetics of formula (I), wherein X, Y, Z and R1 are defined in the description, or a pharmaceutical composition thereof and their use as a medicament, particularly, for the treatment a...
|
|
WO/2023/073534A1 |
Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, Y1, X2, Y2, a, b, c, d, e and f are as defined herein. Also disclosed are lipid nanoparticles comprising a compound of Formula (I) or...
|
|
WO/2023/074847A1 |
The present invention provides: a novel spiro compound having a TRH-DE inhibition activity and useful for the prevention/treatment of various diseases associated with TRH and/or symptoms associated with the diseases, or a pharmacological...
|
|
WO/2023/077041A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/072292A1 |
A compound as shown in the following formula (I-0) or a hydrate, solvate, optical isomer, polymorph, isotope derivative, pharmacologically acceptable salt thereof and a preparation method therefor. The compound can be used for preparing ...
|
|
WO/2023/072794A1 |
The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, Y, Q1, Q2, Q3, Q4 and Q5 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods...
|
|
WO/2023/073966A1 |
This invention addresses the problem of developing a reaction control method for an inverse electron demand Diels-Alder reaction, and a method for producing a cyclocondensation reaction product utilizing a reaction-controlled inverse ele...
|
|
WO/2023/073005A1 |
The invention relates to a 5-aminohexahydro-6,7,8-trihydroxy-3H- oxazolo[3,4-a]pyridin-3-one (i.e. 2,3,4-trihydroxy-5N,6O- oxomethylidene-nojirimycin-l-amine) glycolipid mimetic derivative of formula (I) acting as antagonists or agonist ...
|
|
WO/2023/072913A1 |
The invention provides compounds of formula (I) (I)and pharmaceutically acceptable salts thereof; whereinRa and Rb are both -CH3 or Ra and Rb together form a -CH2-CH2-CH2- or a -CH2-CH2-CH2-CH2-bridging moiety;A is -CH2- or -C(=O)-;T is ...
|
|
WO/2023/066825A1 |
The invention relates to novel compounds having the general formula (Ic) wherein R1, R2, R3, R8, R9, RX, A1, A2, W and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/064587A1 |
The present invention relates to 7,8-dihydro-5H-l,6-naphthyridine derivatives of formula (I) The present compounds are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in treating neurological...
|
|
WO/2023/061432A1 |
A pyrimidine tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound as represented by formula (I), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/061294A1 |
Disclosed are a nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and an application thereof. Particularly, disclosed are a compound as represented in general formula (I), a preparation method therefor,...
|
|
WO/2023/062049A1 |
The invention provides new MAGL inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds,processes of manufacturing the compounds and methods of using the compounds.
|
|
WO/2023/059581A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
|
|
WO/2023/057429A1 |
There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compound...
|
|
WO/2023/060022A1 |
The present disclosure provides new methods of preparing a compound of Formula (I). Such methods can prepare the compound at any scale, including gram and kilogram scale.
|
|
WO/2023/051716A1 |
Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inh...
|
|
WO/2023/051635A1 |
Disclosed in the present invention are a fused ring compound, and a preparation method therefor and the use thereof. Provided in the present invention are a fused ring compound as represented by formula I, a tautomer thereof, a stereoiso...
|
|
WO/2023/051681A1 |
The present invention relates to a four-membered fused ring compound, a preparation method and use thereof, and specifically relates to a four-membered fused ring compound, a preparation method, a pharmaceutical composition containing a ...
|
|
WO/2023/051648A1 |
Provided are a compound as an SHP2 inhibitor, a pharmaceutical composition thereof, and the use thereof in the prevention or treatment of SHP2 activity-mediated diseases.
|
|
WO/2023/048152A1 |
The present invention provides: a compound having a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. A compound represen...
|
|
WO/2023/046135A1 |
Provided are K-Ras mutant protein inhibitors of formula (I), a composition containing the same and the use thereof.
|
|
WO/2023/041756A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the comp...
|
|
WO/2023/039795A1 |
Provided is a novel compound of general formula (I) that inhibits RIP1 kinase or a pharmaceutically acceptable salt thereof. The present invention further relates to a composition containing such a compound, and the use of such a compoun...
|
|
WO/2023/040870A1 |
Provided are novel compounds of general formula (I) that inhibit RIP1 kinase or a pharmaceutically acceptable salt thereof, a composition comprising such compounds, and a use of such compounds in inhibiting programmed necrosis, inhibitin...
|
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
|
WO/2023/044171A1 |
The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are prov...
|
|
WO/2023/040989A1 |
Provided are compounds useful as KRAS G12C inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
|
|
WO/2023/041757A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, A1, A2, A3, A4, A5, A6, L and W are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2023/019351A9 |
Provided is a method of treating a subject with an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, a method of treating a subject with a high risk of developin...
|
|
WO/2023/036156A1 |
The present application relates to a class of DNA-PK selective inhibitors as represented by formula (II), and a preparation method therefor and the use thereof. The use comprises the use of the compound of formula (II) in the preparation...
|
|
WO/2023/036934A1 |
The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I),wherein the variables are as defined in the description and in the claims, which can be used as antiparasitic agents...
|
|
WO/2023/036821A1 |
The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds...
|
|
WO/2023/032940A1 |
The present invention provides a compound which has PDHK inhibitory activity and which is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia...
|
|
WO/2023/030385A1 |
Provided are a pyrimidine-fused cyclic compound represented by formula (A) having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, a pharmaceutical composition contai...
|
|
WO/2023/030517A1 |
Provided are novel compounds useful as KRAS G12C inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
|
|
WO/2023/033018A1 |
The present invention provides a compound represented by formula (I). (In the formula, A1, A2, or A3 each independently is a carbon atom or a nitrogen atom, B1, B2, B3, or B4 each independently is a carbon atom or a nitrogen atom, X1 is ...
|
|
WO/2023/028054A1 |
Described herein are inhibitors of EGFR exon 20 insertion mutants and methods of treating cancer comprising the administration of said inhibitors.
|
|
WO/2023/023880A1 |
The present application belongs to the technical field of catalytic materials, and in particular relates to a nitrogen heterocyclic carbene-urea bifunctional catalyst and a preparation method therefor. The general formula of the molecula...
|
|
WO/2023/023881A1 |
Disclosed is an N-heterocyclic carbene-thiourea bifunctional group catalyst. The structural general formula of the N-heterocyclic carbene-thiourea bifunctional group catalyst is as shown in formula I, and Ar1 and Ar2 in the formula I are...
|
|
WO/2023/025141A1 |
The use of a macrocyclic compound containing amino in the treatment of TRK kinase-mediated tumors. Specifically, the present invention relates to the use of (13E,14E,22R,24S)-12-amino-24,35-difluoro-4-oxa-7-aza-1(5,3)
-pyrazolo[1,5-a]pyr...
|
|
WO/2023/028534A1 |
The present invention relates to novel compounds of Formulae I-XI: wherein each A, A', Q, Q', W, Rw, Y, and Z, and -- are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further r...
|
|
WO/2023/023882A1 |
Disclosed in the present application is a nitrogen heterocyclic carbene-squaric amide bifunctional catalyst. The structural general formula of the nitrogen heterocyclic carbene-squaric amide bifunctional catalyst is as shown in formula I...
|
|
WO/2023/023378A1 |
The invention provides dual -targeted inhibitors of bacterial RNA polymerase having the general structural formula (I): wherein a is a benzoxazino-rifamycin or a spiro-rifamycin; y is a moiety that binds to the bridge-helix N-terminus ta...
|
|
WO/2023/022213A1 |
[Problem] To enable providing of, in a method for producing highly pure everolimus, a low cost purification step which enables efficient acquisition of highly pure everolimus from crude everolimus, and of which the safety has been confir...
|
|
WO/2023/021278A1 |
This invention relates to novel compounds and pharmaceutical compositions comprising novel isoquinolone compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and disco...
|
